Main trial outcomes and intervention
| India | Mozambique | Pakistan | ||||
| Intervention n=6908 | Control n=6109 | Intervention n=6941 | Control n=6239 | Intervention n=18 441 | Control n=17 350 | |
| Trial outcomes | ||||||
| Composite maternal and perinatal outcome (%) | 1252 (18.1) | 1157 (18.9) | 1246 (18) | 1172 (18.8) | 5373 (29.1) | 4187 (24.1) |
| Maternal mortality (%) | 7 (0.1) | 9 (0.1) | 15 (0.2) | 7 (0.1) | 55 (0.3) | 51 (0.3) |
| Maternal morbidity (%) | 371 (5.4) | 325 (5.3) | 735 (10.6) | 690 (11.1) | 2213 (12) | 1728 (10.0) |
| Stillbirth (%) | 191 (2.8) | 156 (2.6) | 196 (2.8) | 162 (2.6) | 935 (5.1) | 951 (5.5) |
| Neonatal death (%) | 179 (2.6%) | 136 (2.2) | 218 (3.1) | 171 (2.7) | 1011 (5.5) | 962 (5.5) |
| Neonatal morbidity (%) | 813 (11.8) | 790 (12.9) | 275 (4.0) | 362 (5.8) | 2375 (12.9) | 1684 (9.7) |
| Intervention | ||||||
| Community engagement sessions | 1379 groups | – | 4243 groups | 1379 groups | 1368 groups 16 691 CHW led | – |
| CHWs trained | 148 | – | 79 | – | 223 | – |
| POM-guided contacts (n) | 57 562 | 26 145 | 54 782 | |||
| POM-guided contacts per pregnancy | 8.0 (3.0, 12.0) | – | 4.0 (2.0, 6.0) | – | 3.0 (2.0, 5.0) | – |
| 0 | 770 (11.1%) | – | 2796 (40.3%) | – | 7905 (42.9%) | – |
| 1–3 | 1268 (18.3%) | – | 936 (13.5%) | – | 2718 (14.7%) | – |
| 4–7 | 1363 (19.7%) | – | 1818 (26.2%) | – | 6008 (32.5%) | – |
| ≥8 | 3507 (50.8%) | – | 1391 (20.0%) | – | 1810 (9.8%) | – |
| Pregnancies given methyldopa (%) | 60 (1.0) | – | 28 (0.7) | – | 93 (0.9) | – |
| Accepted (%) | 51 (85.0) | – | 19 (67.9) | – | 92 (98.9) | – |
| Pregnancies given MgSO4 (%) | 67 (1.1) | – | 28 (0.7) | – | 103 (1.0) | – |
| Accepted (%) | 47 (70.5) | – | 13 (46.4) | – | 73 (70.9) | – |
| Pregnancies referred to facility (%) | 505 (8.2) | – | 263 (6.3) | – | 487 (4.6) | – |
| Accepted (%) | 401 (86.7) | – | 158 (68.4) | – | 305 (83.6) | – |
CHW, community healthcare worker; MgSO4, magnesium sulfate; POM, PIERS (Pre-eclampsia Integrated Estimate of RiSk) On the Move.